Eligible patients were randomly assigned ( @:@ ) centrally with a minimisation procedure to first-line treatment with gemcitabine ( @ mg/m ( @ ) ) and oxaliplatin ( @ mg/m ( @ ) ) with or without cetuximab ( @ mg/m ( @ ) ) , repeated every @ weeks until disease progression or unacceptable toxicity .